Search results for:
levalbuterol
levalbuterol
| Drug Name |
Form |
Strength |
Formulary Unrestricted |
Formulary Restricted |
Non-Formulary |
Interchange |
| Xopenex HFA |
AEROSOL, INHALATION |
CFC free 45 mcg/inh |
|
|
|
|
| Xopenex |
SOLUTION, INHALATION |
0.31 mg, 0.63 mg, 1.25 mg |
|
|
|
|
Last updated: Mar. 3, 2023
Due to national shortage of the nebulization solutions, the formulary status of inhaler products has been temporarily adjusted to formulary, restricted to use during the albuterol/Duoneb shortage. Upon shortage resolution, these products will automatically return to their original formulary status. See Albuterol/Duoneb Shortage Mitigation for more information. (Updated Feb 2023)
The automatic interchange program from albuterol to levalbuterol was discontinued at the August 23, 2006 P&T meeting.
If no specific dose/strength and/or frequency is written, the drug order will be standardized to "levalbuterol 0.63 mg q 8 hours" scheduled, or "0.63 mg q 8 hours prn bronchospasms" for prn orders.
Common Nebulized Doses for Pediatrics
Reviewed: 23 Aug 2006 and 25 Oct 2010 and 25 Mar 2014